• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Johnson & Johnson logs win in Cordis-Medinol stent patent spat

Johnson & Johnson logs win in Cordis-Medinol stent patent spat

August 12, 2014 By Brad Perriello

Johnson & Johnson logs win in Cordis-Medinol stent patent spat

Cordis Corp., the stent-making arm of Johnson & Johnson (NYSE:JNJ), won a round in a legal battle with Medinol over patents covering the coronary stents Cordis hasn’t made for 3 years.

But Medinol, citing a recent U.S. Supreme Court decision, now wants a federal judge to toss her ruling that Medinol waited too long to file the lawsuit, according to court documents and regulatory filings.

Medinol, which won a $750 million decision over erstwhile partner Boston Scientific (NYSE:BSX) in 2005 in another stent war over a related set of patents, accused Cordis in March 2013 of violating 4 of its patents with the Cypher stents, according to the court documents. A year later Judge Shira Scheindlin dismissed the case, ruling on the basis of laches that Medinol’s 8½-year delay in bringing the suit was "unreasonable and inexcusable."

Although Medinol let the deadline for an appeal pass, it asked Scheindlin to reverse, based on the Supreme Court’s May 19 decision in Petrella v. Metro-Goldwyn-Mayer. Medinol argued that the Petrella decision, which followed Scheindlin’s dismissal by a few weeks, "is an intervening change in law that upended the entire laches framework upon which the judgment was based."

"In Petrella, the Supreme Court held that laches is not a defense to an action for copyright infringement brought within the statutory limitation period because laches cannot be used to override a statutory limitation period prescribed by Congress. The holding in Petrella means that laches also cannot be a defense to an action for patent infringement brought within the 6-year limitation period in the patent statute," Medinol claimed last week. "Therefore, Petrella constitutes an ‘extraordinary circumstance’ that justifies the court exercising its equitable discretion to vacate the judgment."

Cordis countered that the Supremes expressly held in Petrella that the decision does not apply to patent law.

"It is perhaps fitting that, having waited 13 years to bring this patent lawsuit and having its lawsuit dismissed on the ground of laches, Medinol now waits 3 months after its time to appeal has expired to raise an issue that it could have raised from the outset," Cordis argued. "Petrella reflects a change in copyright law (at least in the 9th Circuit, whose aberrant rule was reversed by the Supreme Court). The governing law in this case is patent law, not copyright law. Petrella does not change patent law. Indeed … Petrella explicitly states that it is not addressing patent law."

No hearing on the Medinol motion was scheduled as of August 12.

Filed Under: Legal News, News Well, Patent Infringement Tagged With: Cordis Corp., Johnson and Johnson, Medinol Ltd, Stent Wars

More recent news

  • China reportedly launches country’s first invasive BCI trial
  • Neuralink files to raise $649M in new equity offering
  • BofA: Surgical robot remanufacturing not a major setback for Intuitive
  • InspireMD wins CE Mark approval for CGuard Prime
  • Philips reports first cases for VeriSight Pro 3D ICE catheter in Europe

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy